Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18096567rdf:typepubmed:Citationlld:pubmed
pubmed-article:18096567lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:18096567lifeskim:mentionsumls-concept:C0040732lld:lifeskim
pubmed-article:18096567lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:18096567lifeskim:mentionsumls-concept:C0079744lld:lifeskim
pubmed-article:18096567lifeskim:mentionsumls-concept:C1514559lld:lifeskim
pubmed-article:18096567lifeskim:mentionsumls-concept:C0597712lld:lifeskim
pubmed-article:18096567lifeskim:mentionsumls-concept:C1274040lld:lifeskim
pubmed-article:18096567lifeskim:mentionsumls-concept:C0439859lld:lifeskim
pubmed-article:18096567lifeskim:mentionsumls-concept:C1511484lld:lifeskim
pubmed-article:18096567pubmed:issue3lld:pubmed
pubmed-article:18096567pubmed:dateCreated2008-2-28lld:pubmed
pubmed-article:18096567pubmed:abstractTextOverexpression of B-cell lymphoma 2 (bcl-2) protein is a simple biological adverse prognostic factor that could delimit the poor prognosis population candidate for improvement with high-dose therapy and autologous stem-cell transplantation (ASCT) in diffuse large B-cell lymphoma (DLBCL). Therefore, we conducted a risk-adapted phase II study with ASCT as consolidation therapy in low-intermediate risk (LIR) International Prognostic Index patients aged < or = 60 years with bcl-2 overexpression (bcl-2+).lld:pubmed
pubmed-article:18096567pubmed:languageenglld:pubmed
pubmed-article:18096567pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096567pubmed:citationSubsetIMlld:pubmed
pubmed-article:18096567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096567pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18096567pubmed:statusMEDLINElld:pubmed
pubmed-article:18096567pubmed:monthMarlld:pubmed
pubmed-article:18096567pubmed:issn1569-8041lld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:MorelPPlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:GisselbrechtC...lld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:BrièreJJlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:FermiGGlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:LederlinPPlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:TillyHHlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:SallesGGlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:GaulardPPlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:HaiounCClld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:HermineOOlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:MounierNNlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:CopinM CMClld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:TheateIIlld:pubmed
pubmed-article:18096567pubmed:authorpubmed-author:Groupe...lld:pubmed
pubmed-article:18096567pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18096567pubmed:volume19lld:pubmed
pubmed-article:18096567pubmed:ownerNLMlld:pubmed
pubmed-article:18096567pubmed:authorsCompleteYlld:pubmed
pubmed-article:18096567pubmed:pagination560-5lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:meshHeadingpubmed-meshheading:18096567...lld:pubmed
pubmed-article:18096567pubmed:year2008lld:pubmed
pubmed-article:18096567pubmed:articleTitleAutologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2.lld:pubmed
pubmed-article:18096567pubmed:affiliationService d'Hématologie Clinique, Hôpital Schaffner, Lens, France.lld:pubmed
pubmed-article:18096567pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18096567pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:18096567pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed